Patients With Esophageal Cancer(Ⅱ-Ⅲ)
Conditions
Keywords
endostar Esophageal Cancer
Brief summary
a randomized controlled trial of endostar combined with TP regimen(liposomal paclitaxel-carboplatin) for chemoradiotherapy in esophageal squamous cell carcinoma(Ⅱ-Ⅲ)
Detailed description
This study was a controlled clinical trial.A total of 402 patients with pathologically confirmed esophageal squamous cell carcinoma would be enrolled.Patients were randomly divided into two group ,with 201 in the treatment group and 201 in the control group.The treatment group was treated with endostar,chemotherapy (liposomal paclitaxel-carboplatin)and concurrent radiotherapy.The control group was treated with chemotherapy (liposomal paclitaxel-carboplatin)and concurrent radiotherapy .The efficiency and safety would be evaluated. The objective response rate and progress free survival would be analyzed.This data of this study might provide a more effective treatment for esophageal squamous cell carcinoma
Interventions
DRUGendostar+chemoradiotherapy
antiangiogenic drug+chemoradiotherapy
OTHERchemoradiotherapy
chemoradiotherapy
Sponsors
Second Affiliated Hospital of Xi'an Jiaotong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18 to 75 years; 2. Pathology confirmed as esophageal squamous cell carcinoma and Clinical stage is II-III; 3. Initial treatment, No surgery history; 4. ECOG 0\ 2; 5. Expected survival \>=3 months; 6. All the patients should have target lesions that are measurable and evaluable; 7. Should be able to consume liquid diet, no esophageal perforation symptoms, no distant metastases; 8. The main organ function is normal, which meets the following criteria: (1) The standard of blood test should be met (14 days without blood transfusion and blood products, no G-CSF and other hematopoietic stimulation factor correction): Hb\>=100g/L;ANC\>=1.5x10\^9/L;PLT\>=100x10\^9/L; (2) Biochemical inspection shall meet the following criteria: TBIL \< 1.5 ULN; ALT and AST \< 2.0 ULN.Serum Cr is less than 1.5 ULN or endogenous creatinine clearance rate \> 50 ml/min (the Cockcroft Gault formula); (3) Pulmonary function FEV1 \>=1 L or \>50% of corresponding value of normal people; 9\. Female during the reproductive period should be ensured contraception during the study period; 10. Participants voluntarily joined the study, signed informed consent, and had good compliance and follow-up.
Exclusion criteria
1. Patients who do not meet the pathological type of the inclusion criteria and the primary site; 2. Allergic to recombinant endostar, carboplatin, paclitaxel, and contrast agents; 3. Have a distant metastasis; 4. The primary focal tumors or lymph node already had a surgical treatment (except for biopsy), chemoradiotherapy or targeted therapy; 5. Patient who suffered from other malignant tumor; 6. Subject with severe pulmonary and cardiopathic disease history; 7. Pregnant woman or Lactating Women and Women in productive age who refuse take contraception in observation period; 8. Subject with a Personality or psychiatric diseases, people with no legal capacity or people with limited capacity for civil conduct; 9. Received other medicine trials in past 4 weeks; 10. Refuse or incapable to sign the informed consent form of participating this trial; 11. The researchers judged other conditions that could affect clinical research and the results of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| objective response rate(ORR) | Time Frame: approximately 18 months | complete response(CR)+partial response(PR) according to RECIST 1.1 |
| progression-free survival(PFS) | Time Frame: approximately 36 months | progression-free survival is defined as the time from enrollment to the date of first document disease progression or death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| adverse event(AE) | Time Frame: approximately 36 months | adverse event according to NCI CTCAE V4.0 |
| overall survival (OS) | Time Frame: approximately over 3-5 years | overall survival is defined as the time from randomization to death from any cause |
Countries
China
Contacts
Primary ContactHongbing Ma, Doctor tutor
Backup Contactyuxing li, Master
Outcome results
None listed